The Latest Global Survey from ISAPS Reports a Significant Rise in Aesthetic Surgery Worldwide
Total surgical and non-surgical procedures increased by 19.3% MOUNT ROYAL, N.J., Jan. 10, 2023 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, showing a 19.3% overall increase in procedures performed by plastic surgeons in 2021 with more than...
Seoul Business Agency (SBA) Presents “Tech Hub Seoul” Vision in CES 2023 “Effectively inform the global stage about Seoul’s technology and innovation”
SEOUL, South Korea, Jan. 10, 2023 /PRNewswire/ -- The Seoul Metropolitan Government and Seoul Business Agency (SBA) coordinated the Seoul Pavilion in one of the world's largest technology conventions, CES 2023, hosted in Las Vegas, for four days from Thursday, January 5th to Sunday, January 8th. They presented Seoul's vision for the future and promoted its world-class innovative technology...
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the first participant has been successfully dosed in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial...
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for...
Gift of Life Donor Program: Nation’s Leader for 15 Years
Gift of Life Staff, Community & Hospital Partners Continue Proud History of Saving Lives Together PHILADELPHIA, Jan. 9, 2023 /PRNewswire/ -- Gift of Life Donor Program continues to lead the U.S. in life-saving organ donations for a milestone 15 consecutive years thanks to its dedicated staff, hospital partners and generous community. In 2022,...
Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001
SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced the initiation of its RID GOUT Study, a Phase 2b study for Shanton's investigational drug...
Mars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future generations of dogs and cats Mars Petcare Science & Diagnostics President, Nefertiti Greene, hailed...
FlatTech LLC Receives Innovative Technology Contract from Vizient for EpiFaith(R) Syringe for safer epidurals
Contract awarded for products that bring improvement to health care industry TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith® Syringe for epidural has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of EpiFaith® by hospital experts who serve on...
SK bioscience’s Zoster Vaccine Receives Biologics License Application Approval in Malaysia
The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company...
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine against Shingles (Herpes Zoster). JCXH-105...
